Claims
- 1. A culture system for generation of tumor-reactive T lymphocytes comprising four components, incuding a) T cells from a patient with cancer; b) antigen presenting cells; c), autologous or allogeneic tumor cells;, and d) immobilized antibodies to T cell receptors that induce polyclonal activation.
- 2. The culture system of claim 1 where the antigen presenting cells of component b are autologous monocytes that differentiate during the culture due to the cytokines and activation response of the T cells.
- 3. The culture system of claim 1 where the autologous or allogeneic tumor cells of component c are transfected to express at least one gene encoding a molecule that stimulates a direct or indirect T cell response.
- 4. The culture system of claim 1 where the immobilized antibodies of component d bind to CD3 and CD28 receptors.
- 5. A gene of claim 3 comprising DNA encoding anti-CD3 scFv that is expressed at the cell surface.
- 6. The gene of claim 3 comprising DNA encodingG19-4 scFv.
- 7. A gene of claim 3 comprising DNA encoding anti-human 4-1BB scFv at the cell surface.8. A gene of claim 3 comprising DNA encoding 5B9 scFv expressed at the cell surface.
- 8. Autologous or allogeneic tumor cells transfected with a gene encoding anti-CD3 scFv that is expressed on the tumor cell surface
- 9. Autologous or allogeneic tumor cells of claim 8 transfected with G19-4 scFv that is expressed on the tumor cell surface
- 10. Autologous or allogeneic tumor cells transfected with a gene encoding anti-4-1BB scFv that is expressed on the tumor cell surface
- 11. Autologous or allogeneic tumor cells of claim 10 transfected with 5B9 scFv that is expressed on the tumor cell surface
- 12. A method for cancer therapy that includes injecting cancer patients with tumor cells transfected to express anti-CD3 scFv at the cell surface
- 13. A method for cancer therapy of claim 12 that includes injecting cancer patients with tumor cells transfected to express G19-4 scFv at the cell surface.
- 14. A method for cancer therapy that includes injecting tumor cells transfected to express anti-4-1BB scFv at the cell surface.
- 15. A method for cancer therapy of claim 14 that includes injecting cancer patients with tumor cells transfected to express 5B9 at the cell surface.
- 16. A method for cancer therapy that includes injecting cancer patients a with DNA plasmid encoding anti-CD3 scFv at the cell surface.
- 17. A method for cancer therapy of claim 16 that includes injecting cancer patients with a DNA plasmid encoding G19-4 scFv at the cell surface.
- 18. A method for cancer therapy that includes injecting cancer patients with a DNA plasmid encoding anti-4-1BB at the cell surface.
- 19. A method for cancer therapy of claim 18 that includes injecting cancer patients with a DNA plasmid encoding 5B7 scFv at the cell surface.
- 20. DNA for cancer gene therapy encoding anti-CD3 scFv at the cell surface
- 21. DNA for cancer gene therapy encoding G19-4 scFv at the cell surface
- 22. DNA for cancer gene therapy encoding anti-4-1BB at the cell surface
- 23. DNA for cancer gene therapy encoding 5B9 scFv at the cell surface
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims the benefit of provisional patent application No. 60/286,585, filed on Apr. 26, 2001.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] Portions of this work were funded by grants from the United States National Institutes of Health, and the U.S. government has rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60286585 |
Apr 2001 |
US |